<code id='D650AC5A38'></code><style id='D650AC5A38'></style>
    • <acronym id='D650AC5A38'></acronym>
      <center id='D650AC5A38'><center id='D650AC5A38'><tfoot id='D650AC5A38'></tfoot></center><abbr id='D650AC5A38'><dir id='D650AC5A38'><tfoot id='D650AC5A38'></tfoot><noframes id='D650AC5A38'>

    • <optgroup id='D650AC5A38'><strike id='D650AC5A38'><sup id='D650AC5A38'></sup></strike><code id='D650AC5A38'></code></optgroup>
        1. <b id='D650AC5A38'><label id='D650AC5A38'><select id='D650AC5A38'><dt id='D650AC5A38'><span id='D650AC5A38'></span></dt></select></label></b><u id='D650AC5A38'></u>
          <i id='D650AC5A38'><strike id='D650AC5A38'><tt id='D650AC5A38'><pre id='D650AC5A38'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:8343
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          How to improve immunocompromised access to mAb treatments
          How to improve immunocompromised access to mAb treatments

          Monoclonalantibodiesfightagroupofcoronaviruscellsina3Drendering.AdobeAstheU.S.grappleswiththelasting

          read more
          Sports medicine is finally prioritizing gender equality
          Sports medicine is finally prioritizing gender equality

          MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

          read more

          Shionogi licenses Pompe disease therapy from Maze Therapeutics

          MazeTherapeuticsCEOJasonColomaCourtesyAfterseeingitslastdealgobustinthefaceofregulatoryscrutiny,Maze